Disseminated on behalf of MindBio Therapeutics Corp. (CSE: MBIO) (OTCQB: MBQIF) and may include paid advertising. The Intox Collect(TM) technology enhances the…
BioMedWire Editorial Coverage: Biotechnology is undergoing a quiet but profound transformation, one that is reshaping how investors understand value in a…
Designations from established global organizations such as the European Commission carry meaningful implications for biotechnology companies. Soligenix announced that the…
Targeted cancer therapies are increasingly being paired with immunotherapy and chemotherapy to improve outcomes across multiple tumor types First-in-class PP2A…
A survey that was conducted toward the end of last year by Gallup and West Health found that a sizeable…
Soligenix reports clinical update centered on cutaneous T-cell lymphoma (“CTCL”), a rare form of non-Hodgkin lymphoma that primarily affects the…
Lung cancer is the leading cause of cancer-linked fatalities among men and women, and survival beyond five years post-diagnosis is minimal. This…
Oncotelic Therapeutics has recently entered a strategic partnership with TechForce Robotics to commercialize a PDAOAI-enhanced, GMP-compliant robotics platform The collaboration…
For a long time, proton therapy wasn’t available for many cancer patients due to the footprint of traditional proton therapy…
A recent Zacks Small-Cap Research report outlines a number of key milestones that position Soligenix for a potentially eventful period…